Latest News

Tuesday, March 28, 2017 | Clinical Trials, FDA Approval/Clearance, Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story

Tuesday, March 28, 2017 | Dementia & Cognitive Disorders, Research and Publications

New Evidence Suggests Potential for Blood-Based Alzheimer’s Biomarker

Plasma neurofilament light (NFL) may represent a blood-based, non-invasive biomarker in Alzheimer’s disease (AD), according to new findings published in the JAMA Neurology (March 27, 2017). In a…

Read the full story

Friday, March 24, 2017 | Epilepsy & Seizure Disorders, Pain & Headache, Research and Publications

Review Identifies Antidepressants and AEDs Effective for Nerve Pain

A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain. In findings published in the journal Neurology, resea…

Read the full story

Wednesday, March 22, 2017 | FDA Approval/Clearance, Movement Disorders

Novel Adjunct Agent Approved for Parkinson’s "Off" Periods

The FDA approved Xadago (safinamide, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing &ld…

Read the full story

Tuesday, March 14, 2017 | Epilepsy & Seizure Disorders

Sunovion Submits NDA to Expand Aptiom Indication to Pediatric Patients

Sunovion Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the FDA to expand the indication for its antiepileptic drug AED Aptiom (eslicarbazepine acetate) to include use as …

Read the full story

Thursday, February 23, 2017 | Research and Publications, Stroke & Cerebrovascular

ISC 2017: STRATIS Registry Re-Affirms Benefits of Mechanical Thrombectomy from Pivotal Acute Ischemic Stroke Trials

Late-breaking results from the STRATIS (Systematic Evaluation of Patients Treated with Neurothrombectomy Devices for Acute Ischemic Stroke) registry re-affirm the benefits of mechanical thrombectomy t…

Read the full story

Thursday, February 23, 2017 | Research and Publications, Stroke & Cerebrovascular

ISC 2017: Integrative Aspiration System Compares Favorably to Stent Retrievers as Frontline Thrombectomy Therapy for Acute Stroke

New research presented at the ongoing International Stroke Conference in Houston suggests that the ADAPT (A Direct Aspiration, First Pass Technique) compares favorably to the use of stent retrievers a…

Read the full story

Thursday, February 23, 2017 |

World’s Largest Seizure First Aid Training Set to Take Place in March

On March 18, also known as “Purple Day,” the largest seizure first aid training in the world will be attempted at the Mall of America in Minneapolis, MN. The Guinness Book of World Records…

Read the full story

Thursday, February 23, 2017 | Research and Publications, Stroke & Cerebrovascular

ISC 2017: Exercise Significantly Improves Cognitive Impairment After Stroke

New research presented at the ongoing International Stroke Conference 2017 suggests that structured exercise training can significantly improve brain function in stroke survivors. Given the prevalence…

Read the full story

Friday, February 17, 2017 | Neuromuscular & Immune Disorders

FDA Accepts NDA Filing for MT Pharma’s Investigational ALS Treatment

The FDA accepted the Mitsubishi Tanabe Pharma’s New Drug Application (NDA) for edaravone (MCI-186), an intravenous treatment for amyotrophic lateral sclerosis (ALS). Edaravone is described as a …

Read the full story

Friday, February 10, 2017 | Movement Disorders, Phase 3/4 Trials

Inhaled Levodopa Impresses in Treating Parkinson’s OFF Periods in Phase 3 Study

New phase 3 data suggests that the experimental inhaled levodopa, CVT-301 (Acorda Therapeutics), may offer significant improvement in motor function in individuals with Parkinson’s disease exper…

Read the full story

Friday, February 10, 2017 | FDA Approval/Clearance, Neuromuscular & Immune Disorders

New Corticosteroid Approved for Duchenne Muscular Dystrophy

The FDA approved Emflaza (deflazacort) tablets and oral suspension to treat patients age five years and older with Duchenne muscular dystrophy (DMD). Emflaza is the first FDA approved corticosteroid t…

Read the full story

Tuesday, February 07, 2017 | Neuromuscular & Immune Disorders, Research and Publications

Blood Biomarker for Quick and Accurate Prognosis of MS Identified

A newly discovered blood biomarker may aid physicians in identifying the type of multiple sclerosis (MS) in their patients. In a study recently published in Scientific Reports, investigators evaluated…

Read the full story

Thursday, January 26, 2017 | Healthcare Trends

Burnout Affects 60 Percent of US Neurologists

  More than half of practicing neurologists in the US are experiencing some form of burnout, according to a new study published online in Neurology (January 25). The study involved 1,671 neuro…

Read the full story

Thursday, January 26, 2017 | Phase 3/4 Trials, Research and Publications, Sleep

Investigational Narcolepsy Agent Found Effective for Severely Affected Patients with Cataplexy in Phase 3 Study

Results from a phase 3 controlled trial show that pitolisant (Wakix, Bioproject Pharma) may be efficacious in severely affected narcoleptic patients with cataplexy. Pitolisant is a highly-selective hi…

Read the full story
Load More